case_images: PMC9514319_01
case_images: Images during neoadjuvant savolitinib treatment. Enhanced chest CT images of right lung adenocarcinoma before and after the neoadjuvant therapy.
case_images: fonc-12-968030-g001.jpg
case_images: PMC9514319_01_fonc-12-968030-g001.jpg
case_images: f1
case_images: After 4 weeks of treatment, a chest CT scan showed 60% tumor shrinkage and a partial decrease of mediastinal lymph nodes ( Figures 1 ,  2 ).
case_images: Images during neoadjuvant savolitinib treatment. Enhanced chest CT images of lymph nodes before and after the neoadjuvant therapy. The lymph nodes pointed by green arrows.
case_images: fonc-12-968030-g002.jpg
case_images: PMC9514319_01_fonc-12-968030-g002.jpg
case_images: f2
case_images: After 4 weeks of treatment, a chest CT scan showed 60% tumor shrinkage and a partial decrease of mediastinal lymph nodes ( Figures 1 ,  2 ).
case_images: (A) Hematoxylin and eosin (HE) staining. (B) Ki67 staining. (C) Multiple immunohistochemistry staining, including CD8, CD57, CD68, CD163, PD-1, and PD-L1, before and after savolitinib neoadjuvant. (D) Quantitative analysis for staining data. ns, not significant. *p < 0.05; **p < 0.01; ***p < 0.001; ****p <0.0001; (E) Ki-67 index before and after savolitinib neoadjuvant.
case_images: fonc-12-968030-g003.jpg
case_images: PMC9514319_01_fonc-12-968030-g003.jpg
case_images: f3
case_images: The pathological examination showed that the Ki-67 index had dropped to 30% ( Figure 3 ).